Aspirin (salicylate) is a common drug and frequently used long-term in the clinic. It has been well documented that salicylate can cause reversible hearing loss and tinnitus, and diminish outer hair cell (OHC) electromotility, which is capable of actively boosting the basilar membrane vibration and producing acoustic emission. However, aspirin's ototoxic mechanisms still remain largely unclear. In this experiment, the effects of long-term salicylate administration on cochlear hearing functions were investigated by measuring distortion product otoacoustic emissions (DPOAEs) in awake guinea pigs. A single injection of sodium salicylate (200 mg/kg) could reduce the amplitude of the cubic distortion product of 2f 1 -f 2 within 2 hours. The reduction was significant at 20-50 dB SPL stimulus levels and recovered after 8 hours. However, following daily injections of sodium salicylate (200 mg/kg, b.i.d.), the distortion product of 2f 1 -f 2 progressively increased. After injection for 14 days, the distortion product increased about 2-3.5 dB SPL. The increase rate was about 0.2 dB SPL/day. The DP-I/O function remained nonlinear. The increase was greater at 40-70 dB SPL primary sound intensities and reversible. After cessation of salicylate treatment for 4 weeks, the increased distortion product returned to the initial normal levels. The rate of recovery was 0.1 dB SPL/day. In the control animals with saline injection, there was no change in DPOAEs.
Introduction
Otoacoustic emissions are sounds emitted by the cochlea and can be acoustically recordable in the external auditory canal (Kemp 1978) . These emissions provide evidence for an active mechanical amplification of sounds in the inner ear (Wilson 1980; Kim 1980; Rosowski et al. 1984; Norton 1992) . Many experimental data (Probst 1990; Whitehead et al. 1992a, b; Fitzgerald et al. 1993; Frolenkov et al. 1998; Grosh et al. 2004) , including genetic studies (Liberman et al. 2002; Cheatham et al. 2004a) , indicate that these active cochlear mechanics mainly originate from outer hair cells (OHCs). In the mammalian cochlea, OHCs have electromotility that can actively enhance the basilar membrane vibration in response to acoustic stimulation (Brownell et al. 1985) .
Elimination of OHC electromotility can induce hearing loss and also result in elimination or decrease in otoacoustic emissions (Lonsbury-Martin and Martin 1990; Harris 1990; Liberman et al. 2002) . Hence, otoacoustic emission measurement provides a reliable noninvasive test to examine OHC and cochlear functions in vivo.
Salicylate (aspirin) is a widely used drug in clinics. It has been known that salicylate can cause reversible tinnitus and hearing loss (Myers and Bernstein 1965; Matz 1990; Boettcher and Salvi 1991; Brien 1993; Cazals 2000) . Electrophysiological and histological studies suggest that salicylate mainly acts on cochlear OHCs to influence hearing function. Salicylate can reversibly eliminate OHC electromotility. Outer hair cells perfused with salicylate solution show vesiculation of subsurface cisternae in their lateral walls, and a reversible reduction in the turgidity, axial stiffness, electromotility, and motility-associated nonlinear capacitance (Dieler et al. 1991; ShehataDieler et al. 1991; Tunstall et al. 1995; Kakehata and Satons-Sacchi 1996; Lue and Brownell 1997) .
A recent experiment further revealed that salicylate can competitively bind the motor protein prestin with its external voltage sense of Cl -ions to inhibit OHC electromotility (Zheng et al. 2000; Oliver et al. 2001) . In in vivo recording, salicylate reversibly eliminated spontaneous otoacoustic emissions 4 (SOAEs) and reduced distortion product otoacoustic emissions (DPOAEs) acutely after administration (McFadden and Plattsimer 1984; Long and Tubis 1988; Martin et al. 1988; Wier et al. 1988; Kujawa et al. 1992; Fitzgerald et al. 1993; Janssen et al. 2000) . These effects are consistent with hearing loss observed in the clinic after treatment with a high dose of salicylate.
However, it is difficult to reconcile these changes with salicylate-induced tinnitus generation.
Tinnitus is a virtual auditory sense without a corresponding acoustic stimulus, demonstrating hypersensitivity in the auditory system. Many factors can act on central and peripheral auditory systems to induce tinnitus (Jastreboff 1990; Kaltenbach 2000; Salvi et al. 2000; Baguley 2002; Lockwood et al. 2002) . In the clinic, repetitive administration of a relatively high dose of salicylate can uniformly cause tinnitus perception (see a review, Cazals 2000) . Daily treatment with salicylate can also induce animals to develop tinnitus Jastreboff et al. 1988a, b; Guitton et al. 2003) . It has been reported that salicylate increases the spontaneous activity of the auditory nerves (Evans and Borerwe 1982; Stypulkowski 1990) and changes the average spectrum of cochleoneural activity (Schreiner and Snyder 1987; Martin et al. 1993; Cazals et al. 1998 ).
Increased spontaneous neural activities also occurred in the inferior colliculus Chen and Jastreboff 1995; Manabe et al. 1997 ) and the auditory contex (Ochi and Eggermont 1996) . However, the precise mechanism still remains unclear. In this experiment, we adopted recording of DPOAEs in awake guinea pigs to examine the effect of salicylate on cochlear and OHC functions. The data showed that a single injection of salicylate could reduce the amplitude of distortion product of 2f 1 -f 2 in otoacoustic emissions, but long-term administration of salicylate progressively raised the distortion product. This suggested that the long-term administration of salicylate may paradoxically enhance OHC electromotility. The data also provides evidence that
OHCs may play an important role in salicylate-induced tinnitus generation.
Methods

Animal preparation
Adult guinea pigs (250~300g) of either sex with normal pinna reflex and no middle ear infections were used in the experiments. During the DPOAE measurement, the guinea pig was placed in a box in a double-wall soundproof cabin without anesthesia and its head was gently fixed with a nose ring. Before measurement, animals were trained one or two times to accustom them to the testing environment. Most animals were quiet during the recording. The testing would be repeated if the recording was unstable.
Distortion product measurement
A cubic distortion component of 2f 1 -f 2 in DPOAEs was measured using a CELESTA 503
Cochlear Emission Analyzer (Madsen, Denmark). Two plastic tubes with 5-cm long and 3-mm inner diameter were inserted into the external ear canal and sealed with an earplug. Two pure tones (f 1 and f 2 ) were simultaneously delivered into the ear. The ratio of f 2 versus f 1 (f 2 /f 1 ) was 1.22. The test frequency was presented by a geometric mean of f 1 and f 2 [f 0 =(f 1 ×f 2 ) 1/2 ] from f 0 =0.75 to 8 kHz.
The intensity of f 1 (L 1 ) was set at 5 dB SPL (0 dB SPL re. 20 µPa) higher than that of f 2 (L 2 ). The distortion product was recorded from the L 1 /L 2 level of 15/10 dB SPL to 70/65 dB SPL in a step of 5 dB SPL. One hundred-fifty responses were averaged. The recording was set to be automatically stopped when the amplitude of the 2f 1 -f 2 component was lower than 2 standard deviations of the noise floor level.
Salicylate administration and experiment procedure
Sodium salicylic acid was purchased from Sigma (St. Lois, MO, USA) and freshly dissolved in saline to a concentration of 200 mg/ml. In the acute effect study, a single dose of sodium salicylate 6 (200 mg/kg) was administered to 10 guinea pigs through intramuscular injection. The equivalent volume of saline was given to 5 guinea pigs at the same time as control. The distortion product of 2f 1 -f 2 was measured at 30 min prior to the injection and at 2, 4, and 8 hours after the injection. In the long-term administration experiment, sodium salicylate of 200mg/kg was intramuscularly injected into 8 guinea pigs at 9:00 am and 6:00 pm every day for 14 days. Three other guinea pigs were given injection of the equivalent volume of saline as a control group. The distortion product of 2f 1 -f 2 was measured at 30 min prior to the injection at 9:00 am. The day of beginning injection was referred to day 0. Distortion product otoacoustic emissions were measured at day -7 and -3 prior to the administration of salicylate, day 0, 3, 7, 10 and 14 in the injection period, and the 1 st , 2 nd , 3 rd , and 4 th week after cessation of the injection (see Fig. 3 ).
Data analysis
The statistical analyses were performed using a commercial software, SPSS v10.0 (SPSS Inc, Chicago, IL). A level of P<0.01 was accepted as a statistical significance.
This work was approved and carried out in conformity with all applicable regulations and institutional use rules for the use of animals in research.
Results
DPOAEs in normal awake guinea pigs
In this experiment, we measured DPOAEs in awake guinea pigs to study the effects of salicylate on the cochlear function. Fig. 1 shows the distortion product of 2f 1 -f 2 in the normal awake guinea pigs (35 ears). The distortion product of 2f 1 -f 2 shows an increase for the test frequency (f 0 ) from 0.75 kHz to 8 kHz (Fig. 1A) . Inset in Fig. 1A is a recording spectrum showing that the amplitude of 2f 1 -f 2 was about 50 dB SPL at f 0 of 8 kHz and the primary sound pressure levels were 70/65 dB SPL. The recording also had a good repeatability. The distortion product audiograms (DP-gram)
were almost identical in the repeated recordings at different days ( 
Acute effect of single injection of salicylate on DPOAEs
A single salicylate injection could reduce distortion products in acoustic emissions. Fig. 2 shows the reduction in otoacoustic emissions after the single injection of salicylate. The reduction in the distortion product of 2f 1 -f 2 was significant at 2 hours after the injection of salicylate (Fig. 2) . The acute reduction in the distortion product of otoacoustic emissions for salicylate injection was reversible. Eight hours after the injection, the distortion product level had almost recovered to the initial normal level. In the control group with saline injection, the distortion product had no alteration and remained stable during the whole test period (empty circles in Fig. 2 ). . After daily injection of salicylate for 14 days, the distortion product raised about 2-3.5 dB SPL, which was significantly different from the normal level (p<0.01, ANOVA). The increase was reversible. After cessation of the injection of salicylate, the raised distortion product level slowly reduced (Fig. 3 ). Four weeks after cessation of the injection, the distortion product returned to the normal control level and was completely recovered (Figs. 3 and 4A). In the control group with saline injection, there was no change in the distortion product of 2f 1 -f 2 (data not shown). The increase and recovery in the distortion product of 2f 1 -f 2 during long-term administration of salicylate demonstrated linear changes for our experimental period (Fig. 5 ). The slope of increase in the distortion product of 2f 1 -f 2 was about 0.2 dB SPL/day at f 0 =1 kHz to 3 kHz, and 0.15 dB SPL/day at low (0.75 kHz) and high (6-8 kHz) test frequencies (Fig. 5B) . Compared with the increase rate in the injection period, the decrease in the distortion product during the recovery period was slow; the slope of recovery change was about 0.1 dB SPL/day and showed the same recovery rate among the test frequencies (Fig. 5B) . Fig. 7 ), the reduction in the distortion product decreased with sound pressure levels. The change was almost linear except there was a notch at 60/55 dB SPL. The slope of change was 0.2 -0.35 dB SPL. In the control group with saline injection, no change was detectable (empty circles in Fig. 7 ). For longterm administration of salicylate (the right column in Fig. 7 ), the distortion product increased at low sound pressure levels, became saturated and then slightly decreased at high sound pressure levels.
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There was also no significant change in the distortion product in the control group with the saline injection (empty circles in Fig. 7 ). This also demonstrated that the recording in long-term repeated measurements was stable.
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Discussion
Effects of salicylate on otoacoustic emissions and cochlear mechanics
It has been well documented that salicylate can reduce otoacoustic emissions. In the clinic, consumption of aspirin uniformly reduced the SOAEs to levels that were unmeasurable, or approaching the noise floor of the measurement system (Johnsen and Elberling 1982; McFadden and Plattsmier 1984; Long and Tubis 1988; Ueda et al. 1996) . The aspirin also reduced the amplitude of DPOAEs, but did not abolish them. Intracochlear perfusion of salicylate reduced basilar membrane movement (Murugasu and Russell 1995; Grosh et al. 2004 ) and 2f 1 -f 2 distortion products in the ear canal spectrum and in the cochlear microphonic (CM) responses (Kujawa et al. 1992; Fitzgerald et al. 1993; Frank and Kossl 1996) . In in vitro recording, perfusion of salicylate also diminished the electronic distortion products evoked by two sinusoidal stimuli in isolated
OHCs (Takahashi and Santos-Sacchi 1999; Zhao and Santos-Sacchi 1999).
In this study, single salicylate injection could rapidly reduce the amplitude of 2f 1 -f 2 (Fig. 2) ; the decrease was significant at low intensity levels (Figs. 6 and 7) . This is consistent with previous reports that the degree of amplitude reduction was greater at low primary sound levels (Wier et al. 1988 ). It has been reported that intraperitoneal injection of 460 mg/kg sodium salicylate can induce a serum concentration of salicylate at 600-700 mg/L and of about 200 mg/L in the cochlear perilymph within 2-4 hours in the guinea pig . In this experiment, we used 200 mg/kg of sodium salicylate intramuscular injection. The salicylate concentration in the cochlear perilymph would be ~ 90 mg/L (Cazals, 2000) . This concentration of salicylate could reversibly eliminate OHC electromotility in in vitro patch clamp recording (Dieler et al. 1991; Shehata-Dieler et al. 1991; Tunstall et al. 1995; Kakehata and Satons-Sacchi 1996) .
However, long-term administration of salicylate could increase the DPOAE levels (Figs. 3-7) .
As evidenced by their high emission levels, OHCs are obviously functioning. Although there is a debate on the origination and mechanisms of otoacoustic emissions, there is no doubt that the otoacoustic emissions reflect the active cochlear mechanics. In the mammalian cochlea, OHCs have an electromotility capable of actively enhancing basilar membrane vibration (Brownell et al. 1985) , and this electromotility was termed an active cochlear amplifier (Dallos 1992 (Cheatham et al., 2004b) . Long-term use of salicylate may also result in increase in the mechanical nonlinearity associated with stereociliary transduction.
Stereocilia mechanics can produce acoustic emissions (Hudspeth 1997; Liberman et al. 2004 ).
Finally, long-term administration of salicylate may also induce alteration in cyclooxygenase activity to affect active cochlear mechanics. Salicylate can inhibit cyclooxygenase activity (Vane 1971; Mitchell et al. 1993; Vane and Botting 1998) . However, it has been reported that daily intraperitoneal injections of mefenamate, a potent cyclooxygenase inhibitor, did not change the tinnitus-like behavior in animals (Guitton et al. 2003) . It has also been found that intracochlear perfusion of mefenamate had no effect on cochlear function (Puel et al. 1990 ).
The possible mechanisms of salicylate-induced tinnitus generation
Salicylate is a well-known ototoxic drug that can cause reversible tinnitus and hearing loss.
Tinnitus often appears as the first or as an only subjective symptom (Mongan et al. 1973; Day et al. 13 1989) . In the clinic, tinnitus often appears during administration of aspirin (salicylate) after several days to several weeks, becomes louder as treatment is continued, and sounds like a high-pitch noise (McCabe and Dey 1965; Myers and Bernstein 1965; Mongan et al. 1973; Day et al. 1989) .
Behavioral experiments with rats also give evidence of tinnitus occurring after 26 hours of treatment, increasing in loudness with duration of treatment, and having a high pitch (Jastreboff and Sasaki 1994) . Tinnitus is thought to be associated with increased or enhanced auditory neuronal activities. It has been reported that salicylate could increase spontaneous activity of the inferior colliculus Chen and Jastreboff 1995; Manable et al. 1997 ) and the auditory cortex (Ochi and Eggermont 1996; Eggermont and Kenmochi 1998). These changes may cause generation of tinnitus perception. However, the most substantial pharmacological and pathological effects of salicylate occur in the cochlea (Cazals 2000) . At the auditory nerves, salicylate could increase spontaneous activity, broaden tuning curve, and reduce Q 10 values (Evans and Borerwe 1982). Cazals et al. (1998) monitored changes in the average spectrum of electrophysiological cochleoneural activity (ASECA) in long-term administration of salicylate.
They found that the ASECA rose at 1 kHz during the treatment. The increase was reversible and returned to the normal level after cessation of the treatment. It has been hypothesized that imbalance between inner hair cell and outer hair cell activities can trigger tinnitus happening (Jastreboff, 1990) . In this experiment, short-term application of salicylate reversibly reduced the distortion product and long-term administration of salicylate increased the amplitude of 2f 1 -f 2 (Figs.
2-7)
. Both changes could be associated with the OHC activity. This further indicates that OHCs may play an important role in salicylate-induced tinnitus generation.
It has been reported that DPOAEs could be measured in tinnitus affected ears despite the severe hearing loss (Janssen et al. 1998 ). Enhancement of otoacoustic emissions was also reported in temporary noise-induced tinnitus after exposure of a loud low-frequency tone or in acoustic trauma ears with tinnitus (Attias et al. 1996) . In sum, we studied the effects of salicylate on cochlear function by measuring DPOAEs in awake guinea pigs in this experiment. We found that long-term administration of salicylate could paradoxically increase the cubic distortion product of 2f 1 -f 2 . This finding implied that long-term administration of salicylate could enhance active cochlear mechanics. This also suggested that the salicylate-induced tinnitus might be generated at the OHC level. Error bars represent SD. Stars indicate that the distortion product of 2f 1 -f 2 in the salicylate injection group was significantly reduced at 2-and 4-hour points after the injection (p < 0.01, ANOVA). The distortion product almost completely recovered after 8 hours. Histogram analysis of increase in distortion products for long-term administration of salicylate. The difference of 2f 1 -f 2 (∆2f 1 -f 2 ) was calculated from the distortion products at the injection day 14 subtracted by the distortion products measured at the day -3 prior to the injection in the same animals. Error bars represent SD. , and 4 kHz. Solid and empty circles represent differences in changes in the distortion product in the salicylate treated group and the saline control group, respectively. For acute effect, the difference between the distortion products of 2f 1 -f 2 (∆2f 1 -f 2 ) measured at 30 min prior to the injection and at 2 hrs after the injection in the same animal was calculated and then averaged (n=10 and 5 ears for salicylate and saline control groups, respectively). For long-term administration of salicylate, ∆2f 1 -f 2 was calculated from the distortion product at the injection day 14 subtracted by the measurement at the day -3 prior to the injection in the same animal, then averaged (n=14 and 6 ears for salicylate treatment and saline control, respectively). Error bars represent SD. Dotted lines represent data linear fitting. In the right column for long-term effect, only the data points in the low intensity range (below 35/30, 45/40, and 50/45 dB SPL for f 0 =8, 6, and 4 kHz, respectively) were used for fitting. 
